Ocular microtremor in Parkinson’s Disease: Protocol for an observational pilot study
Objective: This study aims to examine OMT in people with PD (PwPD) compared to healthy older adults. Identifying OMT as a PD biomarker could better…Effectiveness of use of Pictographs on Levodopa packaging to ensure awareness of Levodopa/Carbidopa spacing with meals in patients of Idiopathic Parkinson’s disease.
Objective: Food interferes with gastrointestinal absorption of levodopa which requires spacing with meals. This study aimed to evaluate the effect pictographs on Levodopa packaging Fig 1 on increasing patient…Use of concomitant medications before and after treatment with levodopa/carbidopa intestinal gel in patients with advanced Parkinson’s disease: summary of phase 3 and real-world studies
Objective: Evaluate the use of concomitant Parkinson’s disease (PD) medications before and after treatment with levodopa/carbidopa intestinal gel (LCIG) using data from phase 3 clinical…ON/OFF Non-Motor Evaluation: A New Way to Evaluate Non-Motor Fluctuations in Parkinson’s Disease
Objective: To validate an auto-questionnaire allowing a real time evaluation of the severity of NMF in PD. Background: Non-motor fluctuations (NMF) in Parkinson's disease (PD)…Improvement of nocturia symptoms and associated quality of life in patients with Parkinson’s disease treated with foslevodopa/foscarbidopa: results from 2 phase 3 trials
Objective: To assess nocturia over time and its correlation with quality of life (QoL) in patients with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDP/CDP). Background:…Randomized Controlled Trial comparing continuous intrajejunal levodopa infusion and deep brain stimulation for Parkinson’s disease. Cost-effectiveness and cost-utility outcomes of the INVEST study
Objective: To determine the costs of continuous intrajejunal levodopa infusion (CILI) and deep brain stimulation (DBS) for Parkinson’s disease (PD), and to study the cost-effectiveness…Use of levodopa-carbidopa intestinal gel to treat a patient with multiple system atrophy (MSA)
Objective: To describe a case report on the use of Levodopa-carbidopa intestinal gel (LCIG) to treat non-motor symptoms in a patient with multiple system atrophy (MSA) Background: There is no…Social and gender inequity on overall survival and access to deep brain stimulation in Parkinson disease patients in Colombia
Objective: Describe discrepancies on survival and access to DBS in PD in Colombia by gender and affiliation regime. Background: Lower socioeconomic status (SES) has been…Continuity and presence of side effects of continuous subcutaneous apomorphine infusion and levodopa-carbidopa intestinal gel infusion in advanced Parkinson’s disease, in a movement disorder unit in Spain
Objective: To determine the number of patients that maintain infusion therapies (continuous subcutaneous apomorphine infusion (CSAI) and levodopa-carbidopa intestinal gel (LCIG)) as treatment for advanced…Continuous subcutaneous foslevodopa/foscarbidopa: final results from a phase 3, open-label study
Objective: Evaluate safety and efficacy of foslevodopa/foscarbidopa (LDP/CDP) for patients with Parkinson’s disease (PD) in a 52-week, phase 3 study. Background: As PD progresses, patients…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 62
- Next Page »